Processa Pharmaceuticals, Inc., a company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy solicitation process. This filing, known as a Schedule 14A, is a requirement under Section 14(a) of the Securities Exchange Act of 1934 for companies seeking to communicate with shareholders in connection with an upcoming shareholder meeting or vote. The materials filed by Processa Pharmaceuticals are not preliminary, confidential, or part of a definitive proxy statement, but rather additional information to be considered by shareholders. The company has indicated that no filing fee is required for this submission.

Processa Pharmaceuticals, Inc., a company listed in the United States, has filed definitive additional materials with the Securities and Exchange Commission (SEC) as part of its proxy solicitation process. This filing, known as a Schedule 14A, is a requirement under Section 14(a) of the Securities Exchange Act of 1934 for companies seeking to communicate with shareholders in connection with an upcoming shareholder meeting or vote. The materials filed by Processa Pharmaceuticals are not preliminary, confidential, or part of a definitive proxy statement, but rather additional information to be considered by shareholders. The company has indicated that no filing fee is required for this submission.